FDA Requires Stronger Warning About Risk of Neuropsychiatric Events Associated with Asthma/Allergy Medication Singulair and Generic Montelukast. FDA review finds reports of \agitation, depression, sleeping problems, suicidal thoughts and actions. https://t.co/eJPVB3lS3s